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Abstract 
Objective: This study aimed at developing and validating a screening instrument to 
assess premenstrual dysphoric disorder (PMDD) based on DSM-5 criteria, which is not 
yet available. 
Methods: The Premenstrual Dysphoric Disorder Questionnaire for DSM-5 
(Cuestionario del Trastorno Disfórico Premenstrual – DSM-5), a 25-item questionnaire 
to assess PMDD was developed and completed in Spanish by 2,820 women (Age M = 
23.43; SD = 7.87). Exploratory factor analysis (N = 1,410) and confirmatory factor 
analysis (N = 1,410) were performed in randomly selected subsamples. Empirical 
evidence of construct validity was obtained via a multitrait-multimethod approach (N = 
118). Additional validity evidence was provided by associating PMDD with 
Neuroticism. Internal consistency and test-retest reliability were checked.  
Results: Exploratory and confirmatory factor analyses yielded a bi-dimensional 
structure. The first dimension, called Dysphoria, included dysphoric symptoms and 
weight gain; the second dimension, Apathy, referred to apathetic and physical 
symptoms. Both dimensions displayed good internal consistency coefficients 
(Dysphoria’s ordinal alpha = .88; Apathy’s ordinal alpha = .84), and moderate temporal 
stability. The multitrait-multimethod analysis showed that convergent coefficients were 
higher than discriminant coefficients. Furthermore, a positive relationship between 
Neuroticism and PMDD was observed.  
Conclusion: These findings suggest that the instrument is valid and reliable to assess 
PMDD. 
Key words: DSM-5; premenstrual dysphoric disorder; reliability; test development; 
validity.
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1. Introduction 
Before the release of the fifth version of the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-5) [1], premenstrual dysphoric disorder (PMDD) has been 
classified in DSM-IV-TR [2] as a Mood Disorder Not Otherwise Specified. According 
to DSM-IV-TR, 3-5% of women of menstrual age may suffer from the disorder. Of 
these women, 90.6% consider the symptoms to be normal (not pathological) and 18.7% 
seek professional help, although in some cases they receive an inadequate response [3]. 
Nevertheless, due to the salience of PMDD and almost 20 years of research, the disorder 
has now been recognized as a distinct diagnostic entity through its inclusion in the 
newly published DSM-5 [1]. This decision was supported by the work group of experts 
who examined the literature on PMDD and recommended the appropriate criteria for the 
disorder in DSM-5 [4]. Pearlstein [5], O’Brien et al. [6] and Epperson et al. [4] 
suggested that the new category would enhance the legitimacy of the disorder and 
encourage scientists to find more empirical evidence for PMDD and its treatment. This 
is essential for public health and reminds us of the urgent need to fill an obvious gap in 
health care provision. 
The diagnosis of PMDD as described in DSM-5 is based on the fulfillment of 
seven (A to G) criteria (see Table 1). Criterion A refers to the existence of five items in 
most menstrual cycles and to stage-specificity of the cycle. Criterion B and Criterion C 
deal with the specific symptoms of the disorder. Criterion D underscores the clinical 
significance or interference of symptoms with daily-life activities. Criterion E deals 
with the specificity of PMDD as compared with mood and personality disorders. 
Criterion F requests the existence of two month’s daily prospective ratings. Finally, 
Criterion G refers to the absence of a medical or drug-induced cause of the disorder.  
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According to DSM-5[1], the 12-month prevalence rate of PMDD varies between 
1.8% and 5.8% in menstruating women. Although effective treatment for these women 
is necessary, we first need to develop an appropriate assessment tool based on DSM-5 
criteria to assess PMDD. While many prospective and retrospective instruments have 
been developed to evaluate premenstrual disorders, i.e., Endicott et al.’s [7] Daily 
Record of Severity of Problems (DRSP), De la Gándara’s [8] Escala de Trastorno 
Disfórico Premenstrual (TDP), Steiner et al.’s [9] Premenstrual Symptoms Screening 
Tool (PSST), and Steiner et al.’s [10,11] Visual Analogue Scale-MOOD (VAS-
MOOD), none of these tools addresses all the DSM-5 criteria for assessing PMDD, not 
even criteria of the previous DSM IV-TR version [2]. The aim of the present study is, 
therefore, to develop and validate a screening instrument to adequately assess PMDD 
according to DSM-5.  
2. Methods 
2.1. Participants and Procedure for the Item Development  
 The development of the Premenstrual Dysphoric Disorder Questionnaire for 
DSM-5 (in the original Spanish version: Cuestionario del Trastorno Disfórico 
Premenstrual – DSM-5, hereinafter the CTDP – DSM-5) followed a meticulous 
procedure in which five experts in clinical assessment and methodology participated. 
The process involved two phases. 
In the first phase, the PMDD symptom set of DSM-5 was used as a reference for 
creating potential questionnaire items. Based on 11 sets of symptoms, 25 items were 
derived (see Table 1) and formulated in Spanish. In creating these items we generally 
retained words and phrases referring to symptoms, although certain changes were made; 
specifically, we followed Prieto and Delgado’s [12] recommendations regarding the 
wording of items, as well as  the criteria established by Martínez et al. [13] (i.e., 
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representativeness, comprehensibility, and avoiding acquiescence). A dichotomous 
answer format (Yes/No) was chosen to assess the 25 items in order to comply with the 
positive/negative approach traditionally used in clinical diagnosis. Furthermore, the 
instructions urged the respondent to answer Yes only if criteria A and D were met. Then, 
three experts were asked to examine the first version of the tool, and a number of 
changes were made as a result. Words that were difficult to understand were changed 
(e.g., ‘somnolencia’ —‘drowsiness’— instead of ‘letargia’ —‘lethargy’— term) or 
further specified (e.g., next to the word ‘hipersomnia’ —‘hypersomnia’—, its definition 
was added).  
The preliminary version of the tool, composed of 25 dichotomous items, in its 
Spanish version, was then administered to a set of students and staff (N = 128) of a state 
university in Spain. The sample size considered for this data collection fulfilled 
Nunnally’s [14] criterion of being composed at least by 5 participants per item. 
Participants were part of the target population but not of the sample of the experimental 
later stage.  The women who participated in the preliminary and in the whole study 
voluntarily answered the assessment tools after their informed consent was obtained (as 
demanded by the Declaration of Helsinki); almost all women (98%1) were Spanish. This 
first study yielded a PMDD prevalence rate of 50%, which was considered too high, 
given that previous research had reported a frequency of 3-10% [1,2,8,15,16]. 
Furthermore, participants’ questions, doubts and comments about items and instructions 
were reported in Spanish in a report-sheet during data collection, and they were 
qualitatively analyzed later. We, therefore, decided to undertake a second phase in order 
to refine the CTDP – DSM-5. 
In this second phase, two new experts were informed about the outcome of the 
first phase and invited to analyze the preliminary version of the CTDP – DSM-5 in 
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more detail (taking into account the items, response format, and instructions). Further 
changes were made following experts’ advice. Words emphasizing high distress (i.e., 
‘very’, ‘marked’, ‘intense’) were added; items worded as ‘experience’ were re-worded 
as ‘symptoms’. A final table was also included, where respondents were asked (with 
instructions) to link the affirmatively responded items to certain situations that would 
cause disability or interference in daily life (e.g., ‘reduced performance at 
school/college or at work’). The aim of this new section was to ensure the consistency 
of responses and to avoid social desirability and acceptance bias. This version of the 
tool was then administered to a small sample of 32 university students. This time, the 
estimated prevalence of PMDD was about 10%, and the instrument was deemed to have 
a greater capacity to discriminate between a positive and a negative diagnosis of 
PMDD. The next step was therefore to subject this version of the CTDP – DSM-5 to 
empirical validation. 
2.2. Participants and Procedure for the Empirical Validation of the Instrument 
The sample consisted of 2,820 women aged between 18 and 60 years (M = 
23.43; SD = 7.87) affiliated to the University of the Basque Country.2 Women 
studying/working at the university were invited to voluntarily participate in the study. 
The CTDP – DSM-5 was administered to students in a classroom setting by previously 
trained research assistants, after having obtained institutional permission. In the case of 
faculty and staff, the questionnaire was sent to them by email.3 Participants who 
followed specific pharmacological treatments (i.e. hormonal treatments, antidepressant 
or anxiolytic treatments) or who were pregnant in the last year were excluded from the 
study. Furthermore, women with missing values were excluded from the study.4 
To assess the effect of the menstrual phase into the responses, all the participants 
were asked to give the starting date of their last menses and the current date. They were 
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classified into one of the four menstrual cycle phases (premenstrual, menstrual, 
postmenstrual and ovulatory), as established by the Society for Menstrual Cycle 
Research in 1986 [17], by considering the general regular length of the menstrual cycle; 
338 of the women did not answer to this question and were excluded, being the sample 
composed of 2,842 women. 
A subsample of 118 women aged between 18 and 52 years (M = 30.97; SD = 
11.18) was interviewed six months later by a trained, female interviewer who was blind 
to the diagnosis made with the CTDP – DSM-5. The subsample consisted of women 
who were willing to continue participating in the study after the first administration of 
the instrument. Those who obtained a positive diagnosis in the CTDP – DSM-5 (262 
women) and a randomly selected (by a blind researcher) subsample of women with 
negative diagnosis completed a list of 524 women. Out of all these women, those who 
agreed to participate again were interviewed. The Spanish version of the Structured 
Clinical Interview for DSM-IV Axis I Disorders – clinician version (SCID-I) [18] was 
used because a parallel instrument based on DSM-5 was not yet available in Spanish. In 
order to asses PMDD with the interview, a diagnostic algorithm was designed and 
approved by the SCID-I authors. The Spanish version of the PMDD algorithm was 
added to the interview. Additionally, the participants were asked to fill out a daily rating 
scale (Escala de Registro Diario or ERD) during a two-month period. In both cases, the 
aim was to obtain evidence of construct validity based on analyzing the convergent and 
discriminant validity coefficients via a multitrait-multimethod (MTMM) approach [19].  
A further subsample comprising 111 of these 118 women, aged between 18 and 
52 years (M = 30.75; SD = 11.18), answered the questionnaire for a second time to 
assess the test-retest reliability. Finally, along with the CTDP – DSM-5, we 
administered the Spanish version of the NEO-FFI Neuroticism subscale [20] in the 
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whole sample to obtain evidence of validity based on the relationship between PMDD 
and Neuroticism. Previous research has linked PMDD to Neuroticism as a personality 
trait [21]: women suffering from PMDD have been found to present higher levels of 
Neuroticism than non-sufferers [22]. The interest of this study relied on how high levels 
of neuroticism could predict a positive diagnosis on PMDD. For this reason, following 
Kelley’s [23] criteria to divide a variable in upper and lower levels, three levels of 
Neuroticism (“high”, “medium” and “low”) were taken into account. 
2.3. Instruments 
 2.3.1. Cuestionario del Trastorno Disfórico Premenstrual – DSM-5 (CTDP – 
DSM-5) or Premenstrual Dysphoric Disorder Questionnaire for DSM-5.  
This is a retrospective screening scale designed to assess PMDD according to 
DSM-5 criteria. It comprises 25 dichotomous (Yes/No) items (see Table 1).  
2.3.2. Structured Clinical Interview for DSM-IV Axis I Disorders – clinician 
version or SCID-I [18].  
This retrospective interview was created by the authors of DSM-IV [24]. It is a 
reliable and valid instrument designed to assess Axis I disorders [18].  
2.3.3. Escala de Registro Diario (ERD) or Daily Rating Scale.  
This scale was created in Spanish to register the symptoms of PMDD as 
described in the diagnostic criteria B and C of DSM-5. The scale consists of 11 items 
(i.e., the 11 symptom groups of DSM-5) to be answered daily (Yes/No format).  
2.3.4. NEO Five-Factor Inventory (NEO-FFI, in its Spanish version) [20].  
This scale taps the big five personality traits. In the present study, only the 
Neuroticism scale was administered to assess emotional (in)stability by means of 12 
items rated on a 5-point Likert scale (1 = ‘Very inaccurate’, 5 = ‘Very accurate’). Three 
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levels of Neuroticism were taken into account for this study: ‘High’ (> percentile 73), 
‘Medium’ (percentile 27-73), and ‘Low’ (< percentile 27).  
2.4. Data Analysis 
Before starting with the analysis of the psychometric properties of the tool, the 
relationship between the PMDD scores obtained by the CTDP – DSM-5 and the 
menstrual phase in which this score was obtained, was analyzed. Specifically, the 
differences between premenstrual, menstrual, postmenstrual and ovulatory phases were 
examined with Kruskal-Wallis’s non-parametric test using the SPSS v23 program. 
A cross-validation study was carried out to examine the dimensionality of the 
instrument. The first step involved conducting an exploratory factor analysis (EFA) for 
categorical variables in a randomly selected subsample of 1,410 participants. The 
WLSMV estimation method, based on polychoric correlations, and the geomin oblique 
rotation method were applied to determine the factor structure. A confirmatory factor 
analysis (CFA) for categorical variables was then carried out on the polychoric 
correlation matrix in a subsample that included the remaining participants (N = 1,410). 
Both analyses were performed with the Mplus program v7 [25].  
In order to obtain evidence of construct validity of the tool, convergent and 
discriminant coefficients were analyzed via MTMM approach [19], with the Mplus 
program v7 [25]. On the one hand, correlations between PMDD assessed by the CTDP 
– DSM-5, and the same trait assessed by the SCID-I, and the ERD, were estimated to 
obtain convergent validity coefficients (Monotrait Heteromethod correlations). On the 
other hand, correlations between PMDD assessed by the CTDP – DSM-5, and Mood-
Anxiety Disorders and Other Disorders (the remaining disorders), both assessed by the 
SCID-I, were estimated to obtain discriminant validity coefficients (Heterotrait 
Heteromethod correlations). Finally, in order to obtain evidence of the construct validity 
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of the CTDP – DSM-5, the difference between convergent and discriminant coefficients 
was calculated to know whether the mean of the 2 convergent validity coefficients was 
higher in the population than the mean of the 2 discriminant validity coefficients. 
In addition, we used logistic regression for categorical variables to examine 
whether Neuroticism was related to PMDD. This analysis was carried out with SPSS 
(v23). 
In order to analyze the internal consistency of the instrument, the rotated 
reliability of the factors of the CTDP – DSM-5 was estimated for the whole sample (N = 
2,820) following criteria given by Zumbo et al. [26] to estimate the ordinal alpha 
reliability coefficient. Finally, we administered the questionnaire twice over an eight-
month interval to analyze the temporal stability or test-retest reliability. The Pearson 
correlation coefficient between the scores obtained at the two time points was estimated 
for its dimensions. 
3. Results 
The Kruskal-Wallis test showed not statistically significant differences in the 
CTDP – DSM-5 scores as a function of the menstrual phase in which the questionnaire 
was administered (K-W(3) = .78; p = .85).  Effect sizes for all pairs of comparisons 
between menstrual phases were small (Hedges’ g lower than .20). 
3.1. Factor Structure 
First, an EFA was carried out yielding a two factor structure with reasonable 
good fit (RMSEA = .04; CFI = .92; TLI = 90). The first factor, called Dysphoria, 
included dysphoric symptoms (anxiety, depression, the symptoms linked to them, and 
gain in weight) and the second factor, named Apathy, referred to apathetic and physical 
symptoms (see Table 2). Both dimensions explained an important and similar amount of 
variance (21.71% for Dysphoria
 
and 17.20% for Apathy). All items showed a loading 
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higher than .30 on at least one factor, with two exceptions: item 18 (i.e., ‘Very 
significant changes in appetite’) and item 22 (i.e., ‘Evident increase in breast size’). 
Moreover, a simple structure could not be attained for item 22 (i.e., ‘Evident increase in 
breast size’) and item 25 (i.e., ‘Clear gain in weight’) because they had similar loadings 
on both factors. In order to maintain the PMDD construct defined on DSM-5 [1], that is, 
to retain the symptoms included in this classification, we decided to include all items for 
the CFA and for all data analyses. 
Secondly, a CFA was conducted to test the bi-dimensional structure derived 
from the EFA.  The value of the chi-square statistic (χ2 = 706.42; df = 274; p = .0001) 
indicated a lack of fit of the model, but since lower chi-square values indicate better fit, 
the results suggested that our model fitted much better than the baseline model (χ2 = 
5,094.90; df = 300; p = .0001). Furthermore, the sensitivity of the chi-square statistic to 
the violation of the assumptions on which it is based and, specifically, its dependence 
on sample size means that the fit assessment should be based mainly on alternative 
indexes. The values obtained for these indexes showed a reasonable good fit: RMSEA = 
.03; CFI = .91; and TLI = .90.  
3.2. Construct validity 
The convergent validity of the CTDP – DSM-5 was estimated at .53 [95% CI = 
(.43, .64)] based on the correlation between the scores obtained in PMDD assessed by 
the CTDP – DSM-5 and by the SCID-I; and at .55 [95% CI = (.44, .65)] based on the 
correlation between the scores of the CTDP – DSM-5 and the ERD. Regarding 
discriminant validity, a low correlation was found between PMDD assessed by the 
CTDP – DSM-5 and Mood and Anxiety Disorders assessed by the SCID-I [r = .25; 95% 
CI = (.10, .39)]. Additionally, a negative correlation was found between PMDD 
assessed by the CTDP – DSM-5 and Other Disorders assessed by the SCID-I [r = -0.05; 
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95% CI = (-0.20, .11)]. The resulting 95% CI for the difference between the convergent 
and discriminant validity coefficients was (.33, .56). This result suggests, with high 
confidence, that in the population the convergent validity coefficients exceed on average 
the discriminant validity coefficients by an amount that could be as low as .33 and as 
high as .56. This finding is consistent with theoretical expectations, given that 
convergent validity coefficients reflect relationships between different measures of the 
same trait, whereas discriminant validity coefficients reflect considerably weaker 
relationships between different indicators of different traits [19]. 
3.3. Relationship between PMDD and Neuroticism  
Results showed that there was a significantly lower probability of obtaining a 
positive diagnosis of PMDD with the CTDP – DSM-5 when the level of Neuroticism 
was low (B = -.957; df = 1; p = .0001; OR = .384) or medium (B = -.471; df = 1; p = 
.001;OR = .625) than when it was high. This result allows us to support PMDD’s 
validity based on its link to Neuroticism. 
3.4. Reliability 
Both factors, Dysphoria (Ordinal Alpha = .88) and Apathy (Ordinal Alpha = 
.84), have good internal consistency. The temporal stability over an eight-month 
interval was moderate (Pearson correlation index for the two time points for Dysphoria 
= .44 and for Apathy = .64; p < .0001). 
4. Discussion 
The aim of this study was to develop a new retrospective questionnaire with 
adequate psychometric properties to assess PMDD according to DSM-5 criteria. The 
two factor structure of the Premenstrual Dysphoric Disorder Questionnaire for DSM-5 
(CTDP – DSM-5), referring to Dysphoria (dysphoric symptoms and weight gain) and 
Apathy (apathetic and physical symptoms), is in accordance with the available literature 
ASSESSMENT OF PREMENSTRUAL DYSPHORIC DISORDER 13 
 
 
on this construct. In fact, Dysphoria corresponds to Criterion B in DSM-5 and Apathy 
to Criterion C (with the exceptions of items 18, 21 and 25). Concerning reliability, both 
factors showed good internal consistency coefficients and moderate temporal stability. 
In terms of its construct validity, the questionnaire showed greater convergent than 
discriminant validity coefficients in the population. The observed relationship between 
Neuroticism and PMDD further supports its validity. 
The CTDP – DSM-5 has a factor structure with two factors:  Dysphoria concerns 
symptoms linked to anxiety, mood and weight gain; Apathy refers to apathetic or 
physical symptoms. The presence of the symptom weight gain in the first dimension, 
Dysphoria, may be explained through the relationship found between the symptom and 
Neuroticism. This enduring personality trait has been shown to be linked to somatic 
complaints, as well as to distress proneness in general [27]. In the clinical field, patients 
experiencing a difficult condition had reported higher scores on mood symptoms when 
they scored high on Neuroticism [28]. Thus, it may be expected that women diagnosed 
with PMDD, with higher levels of Neuroticism, may display a general disposition to 
experience a greater than the real weight gain, or even a greater increase of the 
mammary size. This means that physical symptoms in PMDD may translate both as a 
dysphoric and as an apathetic component.  
The structure that emerged from our analysis is close to that of other instruments 
such as the Premenstrual Dysphoric Disorder Scale developed by De la Gándara [8], 
where a primary factor called “Dysphoria” and a secondary factor called “Psycho-
physical distress” emerged (instead of only a “physical” factor), and Steiner et al.’s 
[10,11] Visual Analogue Scales where the total scale included a sub-scale called “VAS-
Mood”. 
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In short, our results suggest that within the PMDD construct, the dysphoric 
aspect prevails somewhat. It should be kept in mind that the concept of PMDD as a 
psychiatric disorder was developed on the basis of the notion of premenstrual syndrome 
(PMS), which emerged from a biomedical perspective. Thus, DSM-III-R [29] details 
both physical and emotional changes when describing the symptoms of this disorder. 
However, it should be emphasized that dysphoric symptoms acquired greater 
importance in the conceptual shift from PMS to PMDD, and this is reflected in the 
PMDD criteria that are set out in DSM-IV and DSM-5. This conceptual shift has clear 
implications for future investigation and treatment of the disorder, and should lead to 
the development of research and approaches to clinical assessment that consider the 
whole structure and the two sub-dimensions of PMDD. 
Regarding the instrument’s test-retest reliability, there are a number of possible 
reasons for the finding of moderate temporal stability. First, there was an interval of 
eight months between the administrations of the questionnaire, and the results may 
therefore have been influenced by personal changes occurring during this period 
(emotional, social, financial, etc.) or by the fact that participants responded to the 
questionnaire under different circumstances (for instance, during exam periods vs. the 
holiday season); both aspects could affect the results. Furthermore, the second 
administration of the CTDP – DSM-5 took place two months after administering the 
SCID-I and the ERD, which could also have influenced the results (i.e., through a 
consecutive effect). All these aspects need to be taken into account in future research. In 
any case, it should be noted that a test-retest analysis of the sort carried out here has 
been largely absent from previous research in this field. In fact, this type of analysis has 
only been conducted for two retrospective questionnaires, the Menstrual Distress 
Questionnaire (MDQ) [30] and the shortened Premenstrual Assessment Form (PAF) 
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[31]. The analysis of the MDQ [30] was carried out with a small sample (N = 15) over 
two consecutive menstrual cycles (one-month interval) and found moderate correlations 
(r = .57-.95; p = .01-.05). The analysis of the PAF [31] involved a sample of 217 
women who completed two versions of the tool (the long one with 20 items, and the 
short one with 10 items), over a six-month interval, and also found similar correlations 
to the ones obtained in the present study (r = .60-.70; p = .001). Therefore, there is no 
evidence to suggest that other retrospective questionnaires show better test-retest 
reliability than that observed for the CTDP – DSM-5.    
Regarding construct validity, we found that the CTDP – DSM-5 converged with 
other measures (SCID-I and ERD) of the same trait, while it was able to distinguish 
PMDD from other Axis I disorders. To the best of our knowledge, this is the first 
screening instrument for PMDD for which convergent and discriminant validity have 
been analyzed. Our results confirm that the CTDP – DSM-5 has greater convergent 
validity coefficients than discriminant validity coefficients and, therefore, that it shows 
construct validity. This complies with Landén and Eriksson’s [32] conceptualization by 
considering PMDD as a distinct entity rather than a subtype of depression or anxiety. 
Similar findings were reported by Payne et al. [33], who observed that premenstrual 
symptomatology was different from both bipolar disorder and major depressive 
disorder. The DSM-5 criteria for diagnosing PMDD state that the remaining Axis I 
disorders must be excluded to ensure that symptoms are not due to other disorders, a 
requirement that is fulfilled by the CTDP – DSM-5. In order to provide further evidence 
of its discriminant validity, however, it could be suggested to analyze whether the 
instrument distinguishes between PMDD and reproduction-related disorders (primarily 
dysmenorrhea).  
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However, this study is not without limitations. The long interval between the 
first administration of the CTDP – DSM-5 and the subsequent administration of the 
SCID-I, the ERD and the second administration of the CTDP – DSM-5 implied 
experimental mortality. This could have contributed to the somewhat moderate test-
retest reliability, which was assessed over an eight-month interval, longer than would 
commonly be used with this type of instrument. In addition, the instrument has been 
developed and validated in the Spanish population; the adaptation into other 
languages/cultures would be necessary to generalize its validity to other cultures and/or 
nationalities. 
 Despite these shortcomings, the CTDP – DSM-5 is able to provide a pre-
diagnosis of PMDD, which can then be confirmed subsequently using data from daily 
rating forms of symptomatology across two menstrual cycles. We believe that this study 
constitutes a step forward in research into premenstrual dysphoric disorder because it 
helps to strengthen the theoretical basis of the concept and makes an important applied 
and methodological contribution to the assessment of the disorder. The results should 
serve as a platform for future research in the clinical field. 
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Footnotes 
1
 Students and staff in this university are mainly Spanish (98% in 2015), being the 
remaining  Latin American, European, African, Asian and North American [34]. 
2The University of the Basque Country is the largest university in the Basque region of 
Spain. Due to its public status and reputation for high-quality teaching, students from a 
wide range of socioeconomic backgrounds study at the university. A high percentage of 
young people in the Basque Country (36.19% of women aged between 18 and 23) enroll 
in higher education (Instituto Nacional de Estadística, Spanish Statistical Office) [35].  
3
 A very small proportion of women completed the questionnaire while attending the 
university’s medical service. 
4At the beginning the sample consisted of 3,960 women, but 1,140 were excluded based 
on previously explained criteria. 
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Table 1 
Correspondence of CTDP – DSM-5 Items with the DSM-5 Symptom Groups 
DSM-5 Criteria DSM-5 Symptoms CTDP – DSM-5 Items 
 
Criterion B 
 
1) Affective lability 
 
7. Sensation of being emotionally 
much more vulnerable (i.e., 
attacks of sadness, weeping, or 
greater sensitivity in the face of 
rejection) 
2) Irritability, anger or 
increased interpersonal 
conflicts 
8. Intense and permanent 
annoyance 
9. Intense and permanent 
irritation 
10. Evident increase of intense 
and frequent conflicts with people 
3) Depressed mood, 
feelings of hopelessness, or 
self-deprecating thoughts 
1. Very sad or depressed mood 
2. Intense feelings of 
hopelessness 
3. Very intense thoughts of self-
disapproval 
4) Anxiety, tension, and/or 
feelings of being keyed up 
or on edge 
4. Marked anxiety 
5. Marked tension 
6. Sensation of being overloaded 
or of being close “to the limit”  
 
Criterion C 
 
1) Decreased interest in 
usual activities 
 
11. Evident loss of interest 
towards daily life activities 
(work, school/college)  
12. Evident loss of interest in 
hobbies or leisure activities 
13. Evident loss of interest in 
friends (breaks in social relations)  
2) Subjective difficulty in 
concentration 
14. Considerable difficulty 
concentrating 
3) Lethargy, easy 
fatigability, or marked lack 
of energy 
15. Acute sleepiness, much 
greater sensation of being sleepy 
during the day 
16. Much greater sensation of 
fatigue 
17. Evident lack of energy 
4) Marked change in 
appetite; overeating; or 
specific food cravings 
18. Very significant changes in 
appetite; binges or whims 
regarding specific meals 
5) Hypersomnia or 
insomnia 
19. Acute hypersomnia, that is to 
say, sleeping to excess without 
apparent cause 
20. Insomnia, that is to say, 
finding it really difficult to sleep, 
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or waking up very frequently 
during the night 
6) A sense of being 
overwhelmed or out of 
control 
21. Sensation of being 
overwhelmed or out of control 
7) Physical symptoms 22. Evident increase in breast size 
23. Discomfort in joints or 
muscles 
24. Strong sensation of bloating 
25. Clear gain in weight, with 
difficulty of fitting into clothes, 
footwear, or wearing rings 
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Table 2 
Rotated Factor Structure of the CTDP – DSM-5 
 
Item 
Factor loadings 
Dysphoria Apathy 
1. Very sad or depressed mood .51  
2. Intense feelings of hopelessness .52  
3. Very intense thoughts of self-disapproval .62  
4. Marked anxiety .69  
5. Marked tension .73  
6. Sensation of being overloaded or of being close “to the limit”  .65  
7. Sensation of being emotionally much more vulnerable (i.e., 
attacks of sadness, weeping, or greater sensitivity in the face of 
rejection)  
 
.62 
 
8. Intense and permanent annoyance .81  
9. Intense and permanent irritation .82  
10. Evident increase of intense and frequent conflicts with people .76  
11. Evident loss of interest towards daily life activities (work, 
school/college)  
  
.82 
12. Evident loss of interest in hobbies or leisure activities  .78 
13. Evident loss of interest in friends (breaks in social relations)   .50 
14. Considerable difficulty concentrating  .54 
15. Acute sleepiness, much greater sensation of being sleepy 
during the day 
  
.57 
16. Much greater sensation of fatigue  .67 
17. Evident lack of energy  .82 
18. Very significant changes in appetite; binges or whims 
regarding specific meals 
 
.26 
 
19. Acute hypersomnia, “that is to say, sleeping to excess without 
apparent cause” 
  
.48 
20. Insomnia, that is to say, finding it really difficult to sleep, or 
waking up very frequently during the night 
  
.38 
21. Sensation of being overwhelmed or out of control .60  
22. Evident increase in breast size .25a .26a 
23. Discomfort in joints or muscles  .41 
24. Strong sensation of bloating  .37 
25. Clear gain in weight, with difficulty of fitting into clothes, 
footwear, or wearing rings 
 
.33a 
 
.28a 
Percentage of explained variance 21.71 17.20 
Eigenvalue 5.43 4.30 
Note. aItems 22 and 25 show similar factor loadings on both dimensions; these items’ 
content fall within the domain of the second dimension.  
 
 
